Copyright Reports & Markets. All rights reserved.

Global Non-small Cell Lung Cancer Drugs Market Opportunities and Forecast 2022-2028

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Non-small Cell Lung Cancer Drugs Market Status and Forecast (2017-2028)
      • 1.3.2 Global Non-small Cell Lung Cancer Drugs Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Non-small Cell Lung Cancer Drugs Supply by Company

    • 2.1 Global Non-small Cell Lung Cancer Drugs Sales Volume by Company
    • 2.2 Global Non-small Cell Lung Cancer Drugs Sales Value by Company
    • 2.3 Global Non-small Cell Lung Cancer Drugs Price by Company
    • 2.4 Non-small Cell Lung Cancer Drugs Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Non-small Cell Lung Cancer Drugs Market Status by Type

    • 3.1 Non-small Cell Lung Cancer Drugs Type Introduction
      • 3.1.1 Biologics
      • 3.1.2 Small Molecule Targeted Therapy
      • 3.1.3 Chemotherapy
      • 3.1.4 Other
    • 3.2 Global Non-small Cell Lung Cancer Drugs Market by Type
      • 3.2.1 Global Non-small Cell Lung Cancer Drugs Sales Volume by Type (2017-2022)
      • 3.2.2 Global Non-small Cell Lung Cancer Drugs Sales Value by Type (2017-2022)
      • 3.2.3 Global Non-small Cell Lung Cancer Drugs Price by Type (2017-2022)
    • 3.3 North America: by Type
    • 3.4 Europe: by Type
    • 3.5 Asia Pacific: by Type
    • 3.6 Central & South America: by Type
    • 3.7 Middle East & Africa: by Type

    4 Global and Regional Non-small Cell Lung Cancer Drugs Market Status by Application

    • 4.1 Non-small Cell Lung Cancer Drugs Segment by Application
      • 4.1.1 Lung Adenocarcinoma
      • 4.1.2 Squamous Cell Lung Carcinoma
      • 4.1.3 Large-cell Lung Carcinoma
    • 4.2 Global Non-small Cell Lung Cancer Drugs Market by Application
      • 4.2.1 Global Non-small Cell Lung Cancer Drugs Sales Volume by Application (2017-2022)
      • 4.2.2 Global Non-small Cell Lung Cancer Drugs Sales Value by Application (2017-2022)
      • 4.2.3 Global Non-small Cell Lung Cancer Drugs Price by Application (2017-2022)
    • 4.3 North America: by Application
    • 4.4 Europe: by Application
    • 4.5 Asia Pacific: by Application
    • 4.6 Central & South America: by Application
    • 4.7 Middle East & Africa: by Application

    5 Global Non-small Cell Lung Cancer Drugs Market Status by Region

    • 5.1 Global Non-small Cell Lung Cancer Drugs Market by Region
      • 5.1.1 Global Non-small Cell Lung Cancer Drugs Sales Volume by Region
      • 5.1.2 Global Non-small Cell Lung Cancer Drugs Sales Value by Region
    • 5.2 North America Non-small Cell Lung Cancer Drugs Market Status
    • 5.3 Europe Non-small Cell Lung Cancer Drugs Market Status
    • 5.4 Asia Pacific Non-small Cell Lung Cancer Drugs Market Status
    • 5.5 Central & South America Non-small Cell Lung Cancer Drugs Market Status
    • 5.6 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Status

    6 North America Non-small Cell Lung Cancer Drugs Market Status

    • 6.1 North America Non-small Cell Lung Cancer Drugs Market by Country
      • 6.1.1 North America Non-small Cell Lung Cancer Drugs Sales Volume by Country (2017-2022)
      • 6.1.2 North America Non-small Cell Lung Cancer Drugs Sales Value by Country (2017-2022)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Non-small Cell Lung Cancer Drugs Market Status

    • 7.1 Europe Non-small Cell Lung Cancer Drugs Market by Country
      • 7.1.1 Europe Non-small Cell Lung Cancer Drugs Sales Volume by Country (2017-2022)
      • 7.1.2 Europe Non-small Cell Lung Cancer Drugs Sales Value by Country (2017-2022)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Non-small Cell Lung Cancer Drugs Market Status

    • 8.1 Asia Pacific Non-small Cell Lung Cancer Drugs Market by Country
      • 8.1.1 Asia Pacific Non-small Cell Lung Cancer Drugs Sales Volume by Country (2017-2022)
      • 8.1.2 Asia Pacific Non-small Cell Lung Cancer Drugs Sales Value by Country (2017-2022)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Non-small Cell Lung Cancer Drugs Market Status

    • 9.1 Central & South America Non-small Cell Lung Cancer Drugs Market by Country
      • 9.1.1 Central & South America Non-small Cell Lung Cancer Drugs Sales Volume by Country (2017-2022)
      • 9.1.2 Central & South America Non-small Cell Lung Cancer Drugs Sales Value by Country (2017-2022)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Status

    • 10.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Market by Country
      • 10.1.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Sales Volume by Country (2017-2022)
      • 10.1.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Sales Value by Country (2017-2022)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Non-small Cell Lung Cancer Drugs Manufacturing Cost Analysis
    • 11.5 Non-small Cell Lung Cancer Drugs Sales Channel and Distributors Analysis
      • 11.5.1 Non-small Cell Lung Cancer Drugs Sales Channel
      • 11.5.2 Non-small Cell Lung Cancer Drugs Distributors
    • 11.6 Non-small Cell Lung Cancer Drugs Downstream Major Buyers

    12 Global Non-small Cell Lung Cancer Drugs Market Forecast by Type and by Application

    • 12.1 Global Non-small Cell Lung Cancer Drugs Sales Volume and Sales Value Forecast (2023-2028)
    • 12.2 Global Non-small Cell Lung Cancer Drugs Forecast by Type
      • 12.2.1 Global Non-small Cell Lung Cancer Drugs Sales Volume Forecast by Type
      • 12.2.2 Global Non-small Cell Lung Cancer Drugs Sales Value Forecast by Type
      • 12.2.3 Global Non-small Cell Lung Cancer Drugs Price Forecast by Type
    • 12.3 Global Non-small Cell Lung Cancer Drugs Forecast by Application
      • 12.3.1 Global Non-small Cell Lung Cancer Drugs Sales Volume Forecast by Application
      • 12.3.2 Global Non-small Cell Lung Cancer Drugs Sales Value Forecast by Application
      • 12.3.3 Global Non-small Cell Lung Cancer Drugs Price Forecast by Application

    13 Global Non-small Cell Lung Cancer Drugs Market Forecast by Region/Country

    • 13.1 Global Non-small Cell Lung Cancer Drugs Market Forecast by Region (2023-2028)
      • 13.1.1 Global Non-small Cell Lung Cancer Drugs Sales Volume Forecast by Region (2023-2028)
      • 13.1.2 Global Non-small Cell Lung Cancer Drugs Sales Value Forecast by Region (2023-2028)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Merck & Co., Inc.
      • 14.1.1 Company Information
      • 14.1.2 Non-small Cell Lung Cancer Drugs Product Introduction
      • 14.1.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
      • 14.1.4 SWOT Analysis
    • 14.2 F. Hoffmann-La Roche Ltd
      • 14.2.1 Company Information
      • 14.2.2 Non-small Cell Lung Cancer Drugs Product Introduction
      • 14.2.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
      • 14.2.4 SWOT Analysis
    • 14.3 Eli Lilly and Company
      • 14.3.1 Company Information
      • 14.3.2 Non-small Cell Lung Cancer Drugs Product Introduction
      • 14.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
      • 14.3.4 SWOT Analysis
    • 14.4 Bristol-Myers Squibb Company
      • 14.4.1 Company Information
      • 14.4.2 Non-small Cell Lung Cancer Drugs Product Introduction
      • 14.4.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
      • 14.4.4 SWOT Analysis
    • 14.5 AstraZeneca
      • 14.5.1 Company Information
      • 14.5.2 Non-small Cell Lung Cancer Drugs Product Introduction
      • 14.5.3 AstraZeneca Non-small Cell Lung Cancer Drugs Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
      • 14.5.4 SWOT Analysis

    ...

      15 Conclusion

        16 Methodology

        This report provides a comprehensive analysis of current global Non-small Cell Lung Cancer Drugs market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario. This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Non-small Cell Lung Cancer Drugs industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

        According to this survey, the global Non-small Cell Lung Cancer Drugs market is estimated at $ million in 2021, and projected to grow at a CAGR of % to $ million by 2028.

        Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Non-small Cell Lung Cancer Drugs Market Opportunties and Forecast 2022-2028 report makes a brilliant attempt to unveil key opportunities available in the global Non-small Cell Lung Cancer Drugs market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

        The Global Non-small Cell Lung Cancer Drugs Market has been exhibited in detail in the following chapters
        Chapter 1 displays the basic product introduction and market overview.
        Chapter 2 provides the competition landscape of global Non-small Cell Lung Cancer Drugs industry.
        Chapter 3 provides the market analysis by type and by region
        Chapter 4 provides the market analysis by application and by region
        Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
        Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
        Chapter 12 provides the market forecast by type and by application
        Chapter 13 provides the market forecast by region
        Chapter 14 profiles global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
        Chapter 15 conclusions

        Segmented by Type
        Biologics
        Small Molecule Targeted Therapy

        Segmented by Application
        Lung Adenocarcinoma
        Squamous Cell Lung Carcinoma
        Large-cell Lung Carcinoma

        Segmented by Country
        North America
        United States
        Canada
        Mexico
        Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
        Asia Pacific
        China
        Japan
        Korea
        Southeast Asia
        India
        Australasia
        Central & South America
        Brazil
        Argentina
        Colombia
        Middle East & Africa
        Iran
        Israel
        Turkey
        South Africa
        Saudi Arabia

        Key manufacturers included in this survey
        Eli Lilly and Company
        Bristol-Myers Squibb Company
        AstraZeneca
        Buy now